A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

• Status: Terminated
• Trial end date: 2009-02-01

Summary

A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.

• Phase: Phase 3

Details

• Lead Sponsor: Bayer
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Niacinamide; Paclitaxel; Sorafenib